AbbVie to Acquire Aliada Therapeutics for $1.4 Billion, Expanding Alzheimer's Pipeline
The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...
Daily3d
AbbVie to acquire Aliada Therapeutics for USD 1.4 billion in cash
AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...
biopharma-reporter5d
AbbVie acquires Aliada Therapeutics in $1.4 billion deal
The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...
PharmiWeb6d
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a ...
labiotech20h
Top biotech deals of October 2024
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
PMLiVE5d
AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition
AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...
MM&M3d
Rx Rundown: AbbVie, Biogen, GSK and more
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
Pharmabiz6d
AbbVie to acquire biotechnology company, Aliada Therapeutics for $1.4 billion
AbbVie to acquire biotechnology company, Aliada Therapeutics for $1.4 billion: North Chicago, Illinois Wednesday, October 30, 2024, 09:00 Hrs [IST] AbbVie, an American pharmaceuti ...
The Pharma Letter1d
The week in pharma: action, reaction and insight – week to November 1
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week ...